Clinical informatics
Bring clarity to prostate cancer diagnosis
Transforming complex procedures into confident care
Early and accurate diagnosis leads to clear options for treatment. Unfortunately, standard transrectal ultrasound (TRUS) prostate biopsies are often imprecise, with the ability to detect only 30-41% of cancers.1 Philips offers a comprehensive prostate cancer diagnosis solution in utilizing MR/ultrasound fusion that is in use at 22 of the 25 of the top cancer hospitals in the US.2 This unified, orchestrated approach to prostate cancer diagnosis and care has significant benefits for clinical teams and for patients.
Demonstrated results in prostate cancer diagnosis
Improving prostate cancer detection for more patients
This more targeted approach can benefit patients by potentially reducing instances of biopsy-related hospitalization, decreasing likelihood of sepsis, and most importantly, avoiding the need for repeat biopsies.3
Whichever method is chosen, ensuring that patients have the highest quality care possible can be complicated given the many specialties involved in the prostate cancer journey, such as urology, radiology, pathology, genomics and oncology. Inefficient and disconnected workflows further complicate the picture.
Precise, personalized care starts here
- Philips provides the tools needed for patient-centered MR imaging, advanced visualization and reporting, MR fusion-guided biopsies, and digital pathology.
- This integrated approach unites urology, radiology, pathology, genomics and oncology with a flow of data that streamlines workflows, enhances collaboration for more confidence, delivers meaningful insights and helps support quality of life for patients with prostate cancer.
- Our clinical solutions can further enhance the patient experience by reducing unnecessary biopsies and post-procedure complications.
Our prostate cancer care solutions features:
- High-quality fusion guided procedures start in radiology, and DynaCAD offers advanced visualization tools for real-time analysis, review and reporting of multi-parametric MR studies.
- DynaCAD Urology provides urologists with an easy way to store, review and manage comprehensive diagnostic and therapeutic data.
- UroNav is designed to support you with image guidance during prostate biopsies and focal therapy procedures. It fuses diagnostic MR images of the prostate with live ultrasound images for guided procedures in real time.
Featured solutions for prostate cancer diagnosis
DynaCAD Prostate
High-quality fusion guided procedures start in radiology, and DynaCAD offers advanced visualization tools for real-time analysis, review and reporting of multi-parametric MR studies.
DynaCAD Urology
DynaCAD Urology provides urologists with an easy way to store, review and manage comprehensive diagnostic and therapeutic data. Create time and workflow efficiencies in your prostate cancer care program.
UroNav
UroNav is designed to support you with image guidance during prostate biopsies and focal therapy procedures. It fuses diagnostic MR images of the prostate with live ultrasound images for guided procedures in real time.
The combination of MRI and ultrasound fusion biopsy is extremely powerful. This technology is too good to ignore.
Dr. Edward Steiner
Chair of Wellspan Imaging and Radiation Oncology
Wellspan Health, York, Pennsylvania, USA
Footnotes
- Choi YH, et al. Comparison of cancer detection rates between TRUS-guided biopsy and MRI-targeted biopsy according to PSA level in biopsy-naive patients: a propensity score matching analysis. Clin Genitourin Cancer. 2019 Feb;17(1):e19-e25. doi: 10.1016/j.clgc.2018.09.007. Epub 2018 Sep 13. PMID: 30415878.
- U.S. News and World Report: 2017 Best Hospitals Ranking (Cancer)
- Yarlagadda VK, et al. MRI/US fusion-guided prostate biopsy allows for equivalent cancer detection with significantly fewer needle cores in biopsy-naive men. Diagn Interv Radiol. 2018 May-Jun;24(3):115-120. doi: 10.5152/dir.2018.17422. PMID: 29770762; PMCID: PMC5951198.
- Siddiqui MM, et al. Comparison of MR/ultrasound fusion–guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. JAMA. 2015;313(4):390-397.
- Ahdoot M, et al. MRI-targeted, systematic, and combined biopsy for prostate cancer diagnosis. NEMJ. 2020382:917–928. doi: 10.1056/NEJMoa1910038
Disclaimer
Results from case studies are not predictive of results in other cases. Results in other cases may vary